Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 intravitreal faricimab in Japanese patients with wet AMD and DME
jRCT2080223578Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2017
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of faricimab in exudative macular degeneration and diabetic macular edema (DME) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability of intravitreal faricimab, Systemic pharmacokinetics of faricimab and 1 more. Started Jun 2017; status: completed.
02
Drugs
faricimab
03
Conditions
exudative macular degenerationdiabetic macular edema (DME)
Beyond the preview
Go deeper on jRCT2080223578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223578.